<DOC>
	<DOCNO>NCT01795820</DOCNO>
	<brief_summary>Antiplatelet therapy ticagrelor currently indicate treatment patient present acute coronary syndrome . Such therapy start administration load dose patient yet treatment P2Y12 inhibitor ( antiplatelet agent ) . However unknown whether load dose need maintain satisfactory inhibition platelet aggregation patient already treat previous generation P2Y12 inhibitor ( clopidogrel ) passage new compound ticagrelor . For reason aim present study evaluate level platelet aggregation pharmacological shift clopidogrel ticagrelor perform without load start dose new drug .</brief_summary>
	<brief_title>Platelet Aggregation During Shift From Clopidogrel Ticagrelor</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Acute Coronary Syndrome Current dual anti platelet treatment ASA Clopidogrel No coronary revascularization within previous six month Ongoing therapy ticagrelor , prasugrel ticlopidine enrollment No treatment glycoprotein IIb/IIIa inhibitor within previous 6 day Patients known responder Clopidogrel Known neoplastic autoimmune disease Liver cirrhosis Severe pulmonary disease Known disorder Haemostasis Previous Stroke Ongoing pregnancy Therapy inhibitor P450 Cytochrome 15 day enrollment Low platelet count Hb &lt; 10 g/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>platelet aggregation</keyword>
</DOC>